Physician profile
David Choi
NPI 1922490044
$8,180.24
in general payments reported to CMS, 2019-2025
32 companies · $3,600 in 2025
The $3,600 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $140 · 2021: $360 · 2022: $470 · 2023: $2,169 · 2024: $1,298 · 2025: $3,600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,266 · Travel and Lodging: $778 · Education: $22.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,266.15 |
| Travel and Lodging | $777.51 |
| Education | $22.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,183.01 | 2019-2025 | Rinvoq, Skyrizi, Creon |
| Medtronic, INC. | $1,076.23 | 2023-2025 | Nexpowder, Endoflip, Gi Genius |
| Genzyme Corporation | $497.74 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $465.05 | 2021-2025 | Entyvio |
| Janssen Biotech, INC. | $432.10 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Lilly USA, LLC | $418.32 | 2024-2025 | Omvoh |
| Boston Scientific Corporation | $385.20 | 2023-2025 | Spyglass, Resolution 360 Clip |
| Aimmune Therapeutics, INC. | $362.48 | 2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $293.52 | 2022-2025 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $187.86 | 2023 | Fujifilm |
| Phathom Pharmaceuticals, INC. | $163.92 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $157.35 | 2023-2024 | Andexxa |
| Madrigal Pharmaceuticals | $154.05 | 2025 | Rezdiffra |
| Lucid Diagnostics INC. | $146.15 | 2023 | |
| Celltrion USA INC. | $140.99 | 2024-2025 | Vegzelma, Zymfentra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $133.70 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $132.97 | 2023 | Zeposia |
| Novo Nordisk INC | $120.79 | 2025 | Wegovy |
| Gilead Sciences, INC. | $117.64 | 2020 | |
| Janssen Scientific Affairs, LLC | $114.98 | 2022 | |
| Steris Corporation | $113.82 | 2023 | |
| Celgene Corporation | $81.21 | 2023 | Zeposia |
| Conmed Corporation | $65.76 | 2025 | Conmed Biliary |
| Olympus America INC. | $57.60 | 2023-2025 | Endoclot Phs, Single Use Electrosurgical Knife Kd-655 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.55 | 2024 | Xifaxan |
| Qol Medical, LLC | $28.16 | 2024 | Sucraid |
| Apollo Endosurgery US INC | $23.11 | 2022 | |
| Phadia US INC. | $19.48 | 2023 | Immunocap |
| Fresenius Kabi USA, LLC | $19.45 | 2023 | |
| Alexion Pharmaceuticals, INC. | $19.14 | 2019 | |
| Alfasigma USA, INC. | $12.48 | 2021 | |
| Ardelyx, INC. | $6.43 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.